Mycophenolate mofetil is an immunosuppressive medication that prevents the body from rejecting transplanted organs. Sold under the brand name CellCept, it works by selectively slowing the growth of immune cells that would otherwise attack a new kidney, heart, or liver. It is also widely used off-label to treat autoimmune conditions where the immune system mistakenly attacks the body’s own tissues.
How Mycophenolate Mofetil Works
Mycophenolate mofetil is technically a prodrug, meaning your body converts it into its active form, mycophenolic acid (MPA), after you swallow it. MPA then blocks a specific enzyme that immune cells need to build new DNA and multiply. What makes this drug unusual is its selectivity: most cells in your body can produce the building blocks for DNA through two separate pathways, but certain white blood cells called lymphocytes rely heavily on just one of them. By blocking that single pathway, MPA reduces the supply of a critical DNA component in lymphocytes without significantly affecting other cell types like neutrophils, which help fight bacterial infections through a different route.
The practical result is that your T cells and B cells, the immune cells responsible for recognizing and attacking foreign tissue, slow their reproduction. This is why the drug is effective both for preventing transplant rejection and for calming autoimmune flare-ups where those same cells are causing damage.
Approved and Off-Label Uses
The FDA has approved mycophenolate mofetil for preventing organ rejection in adults and children (3 months and older) who have received a kidney, heart, or liver transplant. In all cases, it is used alongside other immunosuppressive medications rather than on its own.
Beyond transplantation, doctors frequently prescribe it off-label for autoimmune diseases. Lupus nephritis, where lupus attacks the kidneys, is one of the most common off-label uses. It is also prescribed for conditions like vasculitis, certain types of inflammatory muscle disease, and other immune-mediated disorders. In these settings, mycophenolate typically serves as a second-line therapy when initial treatments haven’t worked well enough or when a patient needs to reduce their steroid dose. One study of 106 patients with various immune-mediated diseases found that starting mycophenolate cut the average cumulative steroid dose by more than half over six months, offering meaningful relief from the side effects of long-term steroid use.
Dosage and Formulations
Two forms of mycophenolate are available. Mycophenolate mofetil (CellCept) is the more widely known version, while mycophenolate sodium (Myfortic) uses a different salt formulation with an enteric coating designed to dissolve in the intestine rather than the stomach. The two are not interchangeable milligram for milligram. For adults taking mycophenolate mofetil, the typical total daily dose ranges from 2,000 to 3,000 mg, split into two doses taken roughly 12 hours apart.
Common Side Effects
Gastrointestinal problems are by far the most frequent complaint. Among patients who develop GI toxicity, diarrhea is the dominant symptom, reported in about 78% of cases. Nausea affects roughly 43%, vomiting about 34%, abdominal pain around 31%, and weight loss approximately 28%. These symptoms can range from mild and manageable to severe enough that a dose reduction or switch to the enteric-coated formulation becomes necessary.
Because the drug suppresses immune cell production, drops in white blood cell counts are another well-known risk. This is why regular blood monitoring is a standard part of treatment. Once your levels are stable, your doctor will typically check a complete blood count, kidney function, and liver enzymes at least every 12 weeks for as long as you remain on the medication.
Serious Risks
Mycophenolate carries several boxed warnings, the strongest safety alerts the FDA issues.
Infection
By dampening immune function, mycophenolate increases your vulnerability to serious infections, including bacterial, viral, and fungal infections that can spread throughout the body. There is also a small risk of progressive multifocal leukoencephalopathy (PML), a rare and typically fatal brain infection caused by a virus that is normally kept in check by a healthy immune system.
Cancer
Long-term immune suppression raises the risk of certain cancers, particularly lymphoma and skin cancer. Patients on mycophenolate are generally advised to limit sun exposure, wear protective clothing, and use sunscreen consistently to reduce skin cancer risk.
Pregnancy
Mycophenolate poses severe dangers during pregnancy. Miscarriage rates among women exposed to the drug during pregnancy range from 28% to 64%, compared to roughly 13% to 22% in transplant patients not taking it. In one large registry of kidney transplant recipients, the miscarriage rate was 52% with mycophenolate exposure versus 19% after discontinuing it before conception.
Among pregnancies that do continue, the rate of birth defects is significantly elevated. Data from the same registry showed a 14% birth defect rate in newborns exposed to mycophenolate during early pregnancy, compared to 6% when the drug was stopped before conception and 3% to 5% in the general population. The most common abnormalities involve the ears and ear canals (57% of affected cases), heart defects (31%), cleft lip or palate (31%), and eye abnormalities (26%). Because of these risks, women of childbearing age are required to use effective contraception while on the drug and for six weeks after stopping it.
Drug Interactions to Watch
One interaction that often goes underappreciated involves proton pump inhibitors (PPIs), the acid-reducing medications many people take for heartburn or reflux. Mycophenolate mofetil needs the acidic environment of the stomach to be properly broken down and absorbed. PPIs raise the stomach’s pH, and research shows this can reduce overall drug absorption by 37% and cut peak blood levels by 60%. That drop is clinically meaningful: patients taking a PPI alongside mycophenolate had measurably less immune suppression than those not on a PPI. If you take an acid-reducing medication, your prescriber may need to adjust your mycophenolate dose or consider alternatives.
Antacids containing magnesium or aluminum can also reduce absorption and are generally recommended to be taken several hours apart from mycophenolate rather than at the same time.
What Long-Term Monitoring Looks Like
Staying on mycophenolate safely requires consistent lab work. During the early weeks, blood tests are typically drawn more frequently to catch any sudden drops in white blood cells or changes in kidney or liver function. Once your levels stabilize, the standard monitoring schedule settles to at least every 12 weeks. The core tests include a complete blood count, kidney function markers, liver enzymes, and albumin levels. These routine checks allow your care team to catch problems early and adjust your dose before side effects become serious.